The Food and
Drug Administration Friday issued a public health advisory to warn care
providers and patients that use of common anemia drugs can increase the
risk of death and other serious problems in patients with cancer or
kidney disease.The drugs of concern are Procrit, Epogen and Aranesp,
which are erythropoiesis-stimulating agents. These drugs are genetically
engineered versions of a natural protein, erythropoietin, that increases
the number of red blood cells.